A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada
- 9 May 2024
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (5) , 102115
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 24 references indexed in Scilit:
- Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate CancerClinical Genitourinary Cancer, 2022
- Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based studyBJUI Compass, 2022
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designThe Lancet, 2022
- Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health AdministrationCancer Medicine, 2021
- Apalutamide and Overall Survival in Prostate CancerEuropean Urology, 2021
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2019
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2018
- Apalutamide Treatment and Metastasis-free Survival in Prostate CancerNew England Journal of Medicine, 2018
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015